MicroRNA-145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 1923-1930

  Liu, Yuwu ^a,b,c   Wu, Chang ^d   Wang, Ying ^a,b   Wen, Sailan ^a,b   Wang, Junpu ^a,b   Chen, Zhihong ^a,b   He, Qiongqiong ^a,b   Feng, Deyun ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c XINJIANG MEDICAL UNIVERSITY   (China)

^d Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

Author keywords

ADAM17; Hepatocellular carcinoma; MiR 145; MMP 9

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; GELATINASE B; MESSENGER RNA; MICRORNA 145; UNCLASSIFIED DRUG; MICRORNA; MIRN145 MICRORNA, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BEL 7402 CELL LINE; CANCER INHIBITION; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUH 7 CELL LINE; HUMAN; HUMAN CELL; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SMMC 7721 CELL LINE; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; GENETICS; HEK293 CELL LINE; LIVER TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADAM PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HEK293 CELLS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 9; MICRORNAS;

EID: 84907287062     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3424     Document Type: Article

References (46)

1. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
2. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
3. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006.
4. Kim VN and Nam JW: Genomics of microRNA. Trends Genet 22: 165-173, 2006.
5. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005.
6. Kerr TA, Korenblat KM and Davidson NO: MicroRNAs and liver disease. Transl Res 157: 241-252, 2011.
7. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
8. Takahashi K, Yan I, Wen HJ and Patel T: microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem 46: 946-952, 2013.
9. Sachdeva M and Mo YY: miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2: 170-180, 2010.
10. Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol 302: 1-12, 2007.
11. Zhao C, Xu Y, Zhang Y, et al: Downregulation of miR-145 contributes to lung adenocarcinoma cell growth to form brain metastases. Oncol Rep 30: 2027-2034, 2013.
12. Havelange V, Stauffer N, Heaphy CC, et al: Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer 117: 4696-4706, 2011.
13. Sachdeva M and Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70: 378-387, 2010.
14. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A and Lund AH: MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One 5: e8836, 2010.
15. Noh JH, Chang YG, Kim MG, et al: MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett 335: 455-462, 2013.
16. Cho WC, Chow AS and Au JS: MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 8: 125-131, 2011.
17. Lee HK, Bier A and Cazacu S, et al: MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One 8: e54652, 2013.
18. Doberstein K, Steinmeyer N, Hartmetz AK, et al: MicroRNA.145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 15: 218-230, 2013.
19. Lu Y, Chopp M, Zheng X, Katakowski M, Buller B and Jiang F: MiR-145 reduces ADAM17 expression and inhibits in vitro migration and invasion of glioma cells. Oncol Rep 29: 67-72, 2013.
20. Yang XW, Zhang LJ, Huang XH, et al: miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res 44: 551-559, 2014.
21. Black RA, Rauch CT, Kozlosky CJ, et al: A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385: 729-733, 1997.
22. Mohan MJ, Seaton T and Mitchell J, et al: The tumor necrosis factor-α converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity. Biochemistry 41: 9462-9469, 2002.
23. Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther 8: 1045-1054, 2009.
24. Zheng X, Jiang F, Katakowski M, Lu Y and Chopp M: ADAM17 promotes glioma cell malignant phenotype. Mol Carcinog 51: 150-164, 2012.
25. Lee SO, Jeong YJ, Yu MH, et al: Wogonin suppresses TNF-α.induced MMP-9 expression by blocking the NF-κB activation via MAPK signaling pathways in human aortic smooth muscle cells. Biochem Biophys Res Commun 351: 118-125, 2006.
26. Balasubramanian S, Fan M, Messmer-Blust AF, et al: The interferon-γ-induced GTPase, mGBP-2, inhibits tumor necrosis factor α (TNF-α) induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-κB and Rac protein. J Biol Chem 286: 20054-20064, 2011.
27. Li YQ, Yan JP, Xu WL, et al: ADAM17 mediates MMP9 expression in lung epithelial cells. PLoS One 8: e51701, 2013.
28. Elbashir SM, Harborth J, Weber K and Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26: 199-213, 2002.
29. Krek A, Grün D, Poy MN, et al: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.
30. John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human microRNA targets. PLoS Biol 2: e363, 2004.
31. Yu Q and Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 14: 163-176, 2000.
32. Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688, 2007.
33. Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359, 2008.
34. Kusenda B, Mraz M, Mayer J and Pospisilova S: MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150: 205-215, 2006.
35. McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N and Duffy MJ: ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res 13: 2335-2343, 2007.
36. Kenny PA and Bissell MJ: Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117: 337-345, 2007.
37. Borrell-Pagès M, Rojo F, Albanell J, Baselga J and Arribas J: TACE is required for the activation of the EGFR by TGF-α in tumors. EMBO J 22: 1114-1124, 2003.
38. Karbiener M, Pisani DF, Frontini A, et al: MicroRNA-26 family is required for human adipogenesis and drives characteristics of brown adipocytes. Stem Cells 32: 1578-1590, 2014.
39. Chen YJ and Chang LS: Hydroquinone-induced miR-122 downregulation elicits ADAM17 up-regulation, leading to increased soluble TNF-α production in human leukemia cells with expressed Bcr/Abl. Biochem Pharmacol 86: 620-631, 2013.
40. Tsai WC, Hsu PW, Lai TC, et al: MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571-1582, 2009.
41. Das S, Czarnek M, Bzowska M, et al: ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis. PLoS One 7: e50791, 2012.
42. Xiao LJ, Lin P, Lin F, et al: ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 40: 1714-1724, 2012.
43. Mattu TS, Royle L, Langridge J, et al: O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: implications for the domain organization of the enzyme. Biochemistry 39: 15695-15704, 2000.
44. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
45. Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36, 2012.
46. Klein T and Bischoff R: Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41: 271-290, 2011.